Information Density: TURALIO (Daiichi Sankyo) – Signal Evidence & AI Readability

[H1] TURALIO® (pexidartinib)— The first FDA-approved, oral treatment for TGCT.
Oral therapy: A different way to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery.
TGCT is also known as pigmented villonodular
synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).

Talk to your doctor about TURALIO (available by prescription only).

[H2] What is TURALIO?

TURALIO is a prescription medicine used to treat certain adults who have TGCT that is
not likely to improve with surgery. TGCT is also known as giant cell tumor of the
tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS).
It is not known if TURALIO is safe and effective in children.

[H1] TURALIO® (pexidartinib)— The first FDA-approved, oral treatment for TGCT.
Oral therapy: A different way to treat certain adults who have tenosynovial giant cell tumor (TGCT) that is not likely to improve with surgery.
TGCT is also known as pigmented villonodular
synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).

Talk to your doctor about TURALIO (available by prescription only).

[H2] What is TURALIO?

TURALIO is a prescription medicine used to treat certain adults who have TGCT that is
not likely to improve with surgery. TGCT is also known as giant cell tumor of the
tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS).
It is not known if TURALIO is safe and effective in children.

[H1] What is tenosynovial giant cell tumor (TGCT)?
What is tenosynovial giant cell tumor (TGCT)?

TGCT is typically not cancerous, but it can be life-altering

TGCT is typically not cancerous, but it can be life-altering

TGCT is a type of chronic, rare disease that
can lead to on-going pain and long-term joint damage.
TGCT is a type of chronic, rare disease that
can lead to on-going pain and long-term joint damage.

[H2] TGCT is known by other names

TGCT can be called by different terms, depending on various medical
resources, areas of the world, and some doctors. PVNS, GCT-TS, and TGCT
are
terms that refer to the same disease.

While typically noncancerous (nonmalignant), TGCT is a chronic and
debilitating tumor occurring in or around a joint. It can cause pain,
swelling, stiffness in the affected joint, and other symptoms. TGCT can
reduce the function of small and large joints. In some cases, it can
damage
them. Surgery may be a cure for many people with TGCT. For some,
however,
tumors may grow back after surgery.

GCT-TS, giant cell tumor of the tendon sheath; PVNS,
pigmented
villonodular
synovitis; TGCT, tenosynovial giant cell tumor.

[IMG: PVNS, GCT-TS, and TGCT are terms that refer to the same disease]

[IMG: A TGCT tumor forming]

[H2] What causes TGCT?

Scientists believe that TGCT tumors start in cells that line the joints.
A small number of these cells can have a defect that causes them to make
too much of a protein called colony-stimulating factor 1 (CSF-1). These
defective cells merge and form the tumor.

Extra CSF-1 is thought to work in 2 different ways. It acts like a magnet
to attract inflammatory cells to the joint lining, which causes
swelling, and it causes tumor cells to multiply.

[IMG: A TGCT tumor forming]

[H2] TGCT may return after surgery

Depending on severity, TGCT may return after surgery in 4 years or sooner. The estimated recurrence
rates are up to 15% for localized TGCT
and up to 55% for diffuse TGCT.
In addition to being painful, multiple surgeries limit range of motion
and come with risk of infection.

For patients with TGCT not likely to
improve with surgery, talk to a doctor about TURALIO®
(pexidartinib) as
a treatment option.

[IMG: 4 years icon]

[H2] There are 2 types of TGCT
TGCT is classified into 2 types: diffuse and localized. If
you have TGCT, it’s important to understand the differences between the
2 types and how each can affect your life.

Diffuse TGCT (PVNS)

Localized TGCT (GCT-TS)

Diffuse TGCT
(PVNS)

Localized TGCT
(GCT-TS)

Symptoms and disease features

Diffuse TGCT:
10% to 20% of
all TGCT cases

[IMG: Image representing common locations of diffuse TGCT in the body]

[IMG: Image representing common locations of diffuse TGCT in the body]

The circles represent
common locations of diffuse
TGCT. The large circle indicates the
joint most
commonly affected. Typically, only one
joint is
affected at a time.

[H3] Tumor locations

Tumors are most commonly seen in
large joints

Tumors most often occur in the knee

Tumors can also occur in the hip,
ankle, elbow, and shoulder joints

[H3] Common symptoms

Pain and tenderness
Locking of joint
Swelling (can be due to excess blood
and fluid in the joint)

Limited movement in joint (range of
motion)

[H3]
Features and recurrence (growing back
after treatment)

Tumors are usually larger than 5
centimeters (2 inches)

The borders of the tumors are not
easy to see in surgery

Tumors typically grow in the spaces
between joints and in tissues that
line and surround joints

In some people, the disease may be
linked to joint problems that get
worse over time

Tumors mostly affect one joint and
grow slowly over time

Tumors can recur after surgery in up
to 55% of patients

[H3] Age and gender

Diffuse TGCT tends to affect younger
people, but it can occur in people
of any age

Diffuse TGCT is usually first
diagnosed in adults under 50 years
of age

Reported to be more common in women
than in men

Symptoms and disease features

Localized TGCT:
80% to 90%
of all TGCT cases

[IMG: Image representing common locations of localized TGCT in the body]

[IMG: Image representing common locations of localized TGCT in the body]

The circles represent
common locations of
localized TGCT. The large circle
indicates the
joint most commonly affected. Typically,
only
one joint is affected at a time.

[H3] Tumor locations

Tumors are commonly seen in small
joints

Tumors most often occur in the
fingers and toes

Tumors can also occur in other
joints, such as the wrist, ankle,
foot, knee, elbow, or hip

[H3] Common symptoms

Swelling without pain (most common)

Pain that develops as the tumors
grow (in some patients)

Limited movement in joint (in some
patients), also called limited range
of motion

[H3]
Features and recurrence (growing back
after treatment)

Tumors have a somewhat rounded,
small shape; the borders of the
tumors are easy to see in surgery

Larger tumors can appear in larger
joints

Tumors mostly affect one joint and
grow slowly over time

In rare cases, tumors may lead to
damage of nearby joint or bone, or
they can affect the skin

Tumors can recur after removal by
surgery in up to 15% of patients

[H3] Age and gender

Localized TGCT is typically seen in
people 30 to 50 years of age, but it
can occur in people of any age

Reported to be more common in women
than in men

[H2] Treating TGCT
Learn how TGCT is managed.

Learn more

[H1] Treating tenosynovial giant cell tumor (TGCT)

[H2] There are other TGCT treatment options aside from surgery

Surgery is often the first course of action, but if you and your care
team decide surgery is not likely to improve your condition, there may be
other treatment options available for you.

Depending on severity, TGCT can return after surgery in
4 years or sooner. The estimated recurrence rate for diffuse TGCT is up
to 55%.

[IMG: Up to 55% pie chart icon]

Estimated recurrence rate for diffuse TGCT after surgery

For patients with TGCT not likely to improve with surgery, talk to a doctor about TURALIO® (pexidartinib) as a treatment option.

[H2] About Turalio

Discover the first and only treatment of its kind for TGCT.

Learn more